Committed to Research

Medical Oncology

General Practice

Blacktown Hospital Cancer and Haematology Centre is committed to ensuring cancer patients have access to the latest treatment. As science progresses, clinical trials allow us to innovate, discover new treatments and remain at the forefront of evidence-based care. Clinical trials are a major part of delivering high quality services to ensure our patients have the best possible treatment outcomes.

Blacktown Hospital Cancer and Haematology Centre has:
  • A purpose built cancer clinical trials facility
  • Over 80% of our clinicians hold higher research degrees and most are co-appointed at The University of Sydney
  • An active and exciting trials programme enabling our patients to benefit from early access to the world’s newest medications, treatments, therapies and surgeries
  • A range of trials from early phase studies of new therapies as well as late phase studies

Ultimately, our clinical trials can help to improve the quality of life for patients and lead to better outcomes. We have a large portfolio of clinical trials which represent a large compenet of the research activity of the cancer centre.


Our People

Dr Bo Gao:
Dr Bo Gao is a medical oncologist and clinical researcher at Blacktown and Westmead Hospitals. She completed a PhD in ovarian cancer in 2013 and her main clinic interests are in lung, head and neck, and ovarian cancers. She has led multiple clinical studies in these tumour groups and is also involved in studies of new cancer drugs (Phase 1 studies). She maintains a leadership role in the clinical trial unit at Blacktown Hospital.

A/Prof Matt Carlino:
Matteo Carlino is a Medical Oncologist at Westmead and Blacktown Hospitals, a Clinical Associate Professor at The University of Sydney, and a Faculty Member at Melanoma Institute Australia. He has a research interest in examining biomarkers of response and resistance to both targeted and immunotherapy treated metastatic melanoma and undertook his PhD examining predictors of response and mechanisms of resistance to BRAF and MEK inhibitor treated melanoma.
He continues to be involved in the translational research program based at the melanoma institute and the Westmead centre for medical research. He is an investigator on multiple Phase I,II and III clinical trials in melanoma and other solid tumours.

Dr Mark Wong:
Dr Mark Wong is a senior medical oncologist at Blacktown and Westmead Hospitals and clinical senior lecturer at the University of Sydney. His research focuses on therapeutic drug monitoring and pharmacogenetics of targeted therapies. He has been an investigator on over 30 clinical studies. His main clinical interest is in CNS and gastrointestinal cancers.

Mr Raymond Tangunan:
Raymond Tangunan has been the Clinical Trials Manager of Blacktown Cancer and Haematology Centre – Medical Oncology since February 2016. He was previously Assistant Manager at The Crown Princess Mary Cancer Centre Medical Oncology Clinical Trials Unit. He has been working in oncology trials for 12 years.

A/Prof Adnan Nagrial:
Associate Professor Adnan Nagrial is a medical oncologist and early-career researcher at Westmead and Blacktown Hospitals. He has a research interest in novel cancer therapeutics and completed a PhD investigating biomarkers of therapeutic efficacy in pancreas cancer. His clinical interest is in solid tumour oncology, particularly lung cancers, mesothelioma, colorectal cancer and all other gastrointestinal cancers (oesophageal, gastric, pancreatic, hepatocellular, biliary tract, neuroendocrine). His clinical research focuses on trials in these tumour types and includes early phase cancer drug development, especially in the area of immuno-oncology drugs. He has been an investigator on >25 clinical studies.


Current Research

We currently have more than 70 cancer trials open at Blacktown Cancer and Haematology Centre.

As trials can change rapidly, we would suggest downloading ClinTrial Refer Oncology NSW for the most up to date list of studies available at Blacktown Hospitals. ClinTrial Refer is a mobile smartphone and web-based platform connecting doctors and patients to recruiting clinical trials across research networks. It is available on both Google Play and iTunes and is free to download.


Publications and Reports

  1. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. 2020 Clin. Cancer Res.
  2. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients with Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. 2020 JAMA Oncol.
  3. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic small-cell lung cancer: results from the Keynore-028 and keynote-158 studies. 2020. J. Thorac. Oncol.
  4. Model informed dosing regimen and phase 1 results of the anti-PD-1 antibody budigalimab (ABBV-181). 2020. Clin and Tran Sci.
  5. A fist-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia. 2020. Drug Des. Devel.
  6. Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II keynote-158 study. 2020. J. Clin. Oncol.
  7. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, phase 2 KEYNOTE-158 study. 2020 Lancer Respiratory Medicine


Looking for General
Orientation information?

See more